Metasens 850 Tablet SR contains Metformin hydrochloride 850 mg as its active ingredient, formulated as a sustained-release (SR) tablet to provide extended glycemic control in patients with type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that primarily acts by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This multifaceted mechanism helps to lower both basal and postprandial blood glucose levels without causing significant hypoglycemia when used as monotherapy. Metasens 850 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, especially in overweight patients or those with insulin resistance. The sustained-release formulation allows for once or twice daily dosing, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis, a rare but serious adverse effect. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Metasens 850 Tablet SR should be used under medical supervision, with dose adjustments tailored to individual patient response and tolerability.